Shocking Aussie Study Reveals Vaccine Could Leave You Vulnerable to Gonorrhea—What You Need to Know!

A recent trial of the 4CMenB vaccine, originally developed to prevent meningitis B, confirmed that it is ineffective in preventing gonorrhoea. This finding was presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, where Professor Kate Seib of Griffith University in Australia described the results as “unexpected and somewhat disappointing, but very clear.” The GoGoVax study aimed to explore the vaccine's potential against gonorrhoea, a sexually transmitted infection that affects millions globally.

Gonorrhoea, caused by the bacteria Neisseria gonorrhoeae, affects approximately 82 million people annually worldwide and is particularly concerning for individuals at risk of HIV. Alarmingly, in diverse populations—ranging from gay and bisexual men in Seattle to young women in South Africa—about one in nine individuals acquire gonorrhoea each year. While symptoms are usually mild, the infection is a significant contributor to pelvic inflammatory disease in women, potentially leading to infertility. In rare cases, it can escalate into severe systemic illness, manifesting as joint inflammation, skin lesions, and heart disease.

The emergence of antibiotic resistance in Neisseria gonorrhoeae adds to the urgency of finding effective prevention methods. Currently, this bacterium has shown resistance to multiple antibiotic classes, with only ceftriaxone remaining largely effective against most infections. New antibiotics like gepotidacin and zoliflodacin were licensed by the US Food and Drug Administration in December 2025 for treating multi-drug-resistant gonorrhoea, but early signs of resistance have already emerged against these options.

In the UK, diagnoses of gonorrhoea surged, more than doubling from 37,150 in 2013 to 82,592 in 2022. In response, the National Health Service began offering the Bexsero vaccine to individuals at high risk of gonorrhoea, a move echoed by the Galicia region of Spain. Professor Seib emphasized the necessity of continuing research into new prevention strategies to tackle gonorrhoea, despite this setback.

In the GoGoVax study, 620 gay and bisexual men, as well as trans and non-binary individuals, were randomly assigned to receive either the Bexsero vaccine or a placebo across two doses three months apart. The study was designed to offer the placebo group a chance to receive the vaccine after the two-year trial if it proved effective. Of the participants, 587 completed both doses and attended all clinic visits, which included three-monthly STI check-ups and tissue samples from infection sites (urethra, rectum, or throat) at designated intervals.

Participants had an average age of 34, with 98% identifying as cisgender men. Notably, 10% were HIV-positive, and a substantial 90% had a history of gonorrhoea. Alarmingly, 35% reported never using condoms, and 60% had more than ten sexual partners in the preceding six months. The results were sobering; the vaccine showed no efficacy whatsoever in preventing gonorrhoea. The annual incidence of new gonorrhoea diagnoses was 48% for both vaccine and placebo groups, with any infection incidence at 60% and 61%, respectively.

Symptomatic gonorrhoea incidence was 9% for vaccine recipients and 9.5% for those on placebo, indicating that less than one in five infections presented with symptoms. Among HIV-positive participants, the incidence was 51% for vaccine recipients versus 87% for placebo, a 41% difference that, while noteworthy, did not reach statistical significance due to the small sample size. The same lack of significance applied to other subsets, including transgender/non-binary individuals and younger men.

The findings of the GoGoVax study align with the earlier French DoxyVAC trial, which also failed to demonstrate clear efficacy of the 4CMenB vaccine against gonorrhoea. Despite these disappointing results, Professor Seib cautioned against generalizing findings to other populations, particularly cisgender women, where the infection’s transmission dynamics and risks differ. Two additional large-scale randomized studies are currently underway: the MAGI study, investigating 2,200 men and women in the US, Malawi, and Thailand, and the BIYELA study, focusing on 1,100 young women in South Africa.

As global efforts to combat gonorrhoea continue, the need for effective prevention strategies remains pressing. The ongoing rise in infection rates and growing antibiotic resistance highlight the importance of sustained research and innovation in this critical area of public health.